Primarily for ulcerative colitis patients who want to understand their own disease patterns, track symptoms between appointments, and arrive at their gastroenterologist with objective data rather than subjective descriptions.

Secondarily useful for caregivers managing a family member's ulcerative colitis, and for clinicians who want patients to arrive better prepared. The platform is bilingual, English and Turkish, expanding its reach to Turkish-speaking ulcerative colitis patients.

Two complementary sources power the platform:

The custom LLM performs sentiment analysis, co-occurrence detection, and statistical correlation across both sources. Confidence intervals are calculated for each detected pattern.

No. Ulcerative Colitis Insights is explicitly for informational purposes only. Content is based on AI analysis of patient community data and is not a substitute for professional medical consultation, diagnosis, or treatment. The platform carries a medical disclaimer and advises users to consult their gastroenterologist before making any changes to their treatment plan.

Its role is to bridge the information gap, giving patients the language, data, and context to have better conversations with their doctors, not to replace those conversations.

Bowel urgency is the most disruptive symptom of ulcerative colitis in daily life, yet it is consistently underreported in both clinical trials and patient–HCP interactions. Patients describe "bathroom mapping", being aware of every bathroom location before leaving home, as a constant burden.

The data from Ulcerative Colitis Insights' cohort shows 69% of patients report urgency (n=8,800). Clinical research shows 54% experience it even during remission, and 32% of those patients with urgency during remission meet criteria for IBS, an overlap almost never addressed in gastroenterology appointments.

Ulcerative Colitis Insights' cohort data shows 79% of patients have a measurable stress→symptom spike link within 48 hours. This is the strongest single lifestyle correlate in the dataset, stronger than most food triggers for most patients.

Clinically, stress is a known gut-brain axis modulator in IBD. It does not cause ulcerative colitis, but it reliably worsens flares in susceptible patients. By logging stress daily and correlating it with the 48-hour symptom window, the tracker turns an abstract "stress worsens my ulcerative colitis" into a quantified, personal data point that can be shown to a gastroenterologist.

Patients also often underestimate their chronic baseline stress level when asked verbally in a clinical setting. The daily logged average reveals it objectively over time.

A 2025 study in Sleep Medicine found ulcerative colitis patients sleeping under 6 hours showed 3× higher disease activity scores, establishing sleep as a major modifiable risk factor. This makes sleep one of the highest-value lifestyle metrics to track.

Poor sleep disrupts circadian rhythm, which directly affects gut microbiome composition and mucosal immune function. The tracker captures both hours slept and quality rating, allowing the pattern model to detect whether it is sleep duration or quality that predicts that individual's flares.

Your personal health data is stored on your device and securely synced to your encrypted cloud account (powered by Supabase). Data is encrypted in transit with TLS and at rest with AES-256. Row-Level Security ensures only you can access your data — not even the UCInsights team can read it.

Cloud sync means you never lose your health history if you switch phones or lose your device. Your data is tied to your account, not to a single device. We never sell, share, or use your personal health data for advertising or AI training. You can request full account and data deletion at any time by emailing info@ucinsights.org.

The UCAI score is available from day one, it computes from each day's inputs immediately. The 48-hour pattern model begins from the third day of logging.

The matrix cross-references 5 key lifestyle inputs (stress, sleep, food, activity, medication adherence) against 5 symptom outputs (bowel frequency, urgency, pain, bleeding, fatigue) to identify which input combinations have the strongest personal correlation with symptom spikes.

This produces a ranked list of personal triggers rather than generic population-level advice. The 79% population stress→symptom link is a baseline, the matrix finds whether that applies to this individual and which combination is most predictive for them specifically.

The 48-hour window is grounded in the population data: 79% of the Ulcerative Colitis Insights cohort shows a stress→symptom spike within 48 hours of a stress event. Food transit time through the gastrointestinal tract is typically 24–48 hours, meaning a dietary trigger often manifests 1–2 days later, not the same day.

A same-day-only model would miss most trigger relationships. The 48-hour window captures the biological delay between cause and symptom manifestation in ulcerative colitis.

The full Mayo Score (0–12) requires four components: stool frequency, rectal bleeding, physician's global assessment, and endoscopic findings. The last two require clinical involvement, a physician's in-room rating and a colonoscopy. Neither is possible daily.

The Simplified Mayo Score uses only stool frequency and rectal bleeding, both directly logged by the patient in the health tracker. This makes it computable from app inputs without any clinical involvement while retaining clinical meaning as a validated IBD endpoint.

The remission definition gap is one of the most significant doctor–patient communication failures in ulcerative colitis. Research confirms no unified definition exists between patients, physicians, and regulators.

The UCAI score grounds both sides in a shared number. A score of 0–1 means clinical remission by Simplified Mayo criteria. If a physician says "you're in remission" but the patient's UCAI is 3, there is a conversation to have, enabled by data that both sides recognize.

This is the information a gastroenterologist cannot gather in a 10-minute appointment. A patient arriving with "my last 3 flares all followed two consecutive nights under 5 hours sleep plus high stress" is a fundamentally different clinical conversation than "I've been stressed lately."

It also changes the treatment conversation. A patient whose triggers are primarily lifestyle-based (sleep, stress) has different management priorities than one whose triggers are primarily dietary or medication-adherence-related. Trigger discovery makes this visible to both patient and doctor.

Questions can be asked in English or Turkish. The bilingual capability is built into the Community Search Assistant module, which is the conversational layer on top of the AI search.

Yes, via the Personal Health Profile. When a patient saves their ulcerative colitis type, diagnosis year, baseline bowel pattern, and current medications, they can opt in to have every AI answer personalized with their own health context. A question about Entyvio effectiveness returns results filtered to patients with a similar profile, not the entire 15,600-patient cohort.

Two clinical benefits: normalization and language. Knowing 69% of ulcerative colitis patients experience urgency normalizes it, making patients more likely to raise it with their doctor rather than assume it is untreatable or embarrassing. Knowing the exact prevalence number gives patients the language to quantify their experience in clinical terms rather than subjective descriptions.

Many ulcerative colitis patients assume their symptoms are unusual or that they are handling their disease worse than others. Population data corrects this, and makes patients more likely to engage honestly with their care.

The medication trends module fills a gap that clinical research data does not cover: real-world patient experience between clinical trial conditions and daily life. RCTs report efficacy under controlled conditions; community data captures how medications perform for real patients with varying adherence, diet, and lifestyle factors.

Research from 2025 (Frontiers in Health Services) found ulcerative colitis patients feel left alone to cope with rectal therapy challenges, pre-use concerns and difficulties after first use are not adequately addressed by clinicians or pharmacists. This is a specific gap the medication trends data, combined with the Medication Manager's reminder system, partially addresses.

Community data on rectal formulations (suppositories, enemas) reveals real adherence patterns, practical tips, and common failure modes that no clinical trial documents, giving patients context that HCPs rarely provide.

Diet is one of the most frequently asked-about topics for ulcerative colitis patients and one of the most poorly answered by clinical resources. Clinical guidelines can recommend a Mediterranean diet reduces flare risk by 40% (2025 Journal of Crohn's and Colitis) but cannot tell an individual patient which specific foods affect their specific disease.

The food sentiment data fills the gap between population-level dietary guidelines and individual food choices, giving patients a starting point for self-experimentation grounded in what 15,600 other patients have experienced.

Community food sentiment gives a population baseline. Personal meal logging in the health tracker, combined with trigger discovery, reveals whether a given patient deviates from that baseline. If 78% of patients tolerate bananas but this patient's trigger discovery flags banana consumption before flare days, the personal data overrides the population recommendation.

This is the intended workflow: community data informs initial choices, personal data refines them over time.

Ulcerative colitis requires long-term maintenance therapy to prevent relapse. Studies show up to 40–50% of ulcerative colitis patients on 5-ASA maintenance therapy are non-adherent, and non-adherence is associated with a 5-fold increased risk of relapse compared to adherent patients.

Many patients stop taking medication when they feel well, the remission paradox. Rectal formulations are particularly prone to non-adherence due to practical difficulties that are rarely discussed in clinical visits. The medication manager addresses both the remission paradox (ongoing reminders even when feeling well) and the practical gap (reminder-based habit formation for complex dosing regimens).

Each day the patient confirms medication taken, the tracker logs it as an adherence data point. The 48-hour pattern model can then correlate missed doses with symptom spikes in the subsequent 24–48 hours, turning missed doses from an invisible factor into a visible trigger.

This is particularly valuable for patients on biologics with scheduled infusions or injections. Missing a scheduled dose of a biologic with a 4–8 week dosing interval can cause loss of remission that appears weeks later with no obvious cause. Logged adherence data makes that connection visible.

When the profile is completed and personalization is opted in, every AI search answer filters the 15,600-patient cohort to patients with a similar profile before generating the response. A question about urgency during remission returns data specifically from patients with the same ulcerative colitis extent and on the same medication, not the full cohort average.

The three layers are designed to be used together: population data sets expectations, personal data refines them, personal analytics translates them into appointment-ready evidence.

The 15,600 patient reports are primarily sourced from Reddit r/UlcerativeColitis and IBD forums. This introduces selection bias: forum users skew toward patients with more severe or harder-to-manage disease (those with mild, well-controlled ulcerative colitis rarely seek online community support). Prevalence data from this cohort may overestimate symptom burden relative to the general ulcerative colitis population.

Additionally, community medication remission data reflects subjective patient-reported improvement, not clinical or endoscopic remission as defined in RCTs. The 78% Entyvio community response rate is not directly comparable to the 60% GEMINI RCT figure, different definitions are being measured.